Extreme variability in succinylcholine dose for muscle relaxation in electroconvulsive therapy

Area of Science:

• Anesthesiology
• Neurology
• Pharmacology

Background:

• Succinylcholine is a common neuromuscular blocking agent used in electroconvulsive therapy (ECT).
• Determining the optimal dose is essential for patient safety and treatment efficacy.
• Variability in patient response necessitates dose adjustments.

Purpose of the Study:

• To identify the range of succinylcholine doses that fall outside 2 standard deviations (SD) of the mean optimal dose (0.9 mg/kg) in ECT.
• To understand the dosing variability required for adequate neuromuscular blockade in a diverse patient population.

Main Methods:

• Retrospective chart review of patients undergoing ECT over a 5-year period.
• Analysis of initial and adjusted succinylcholine doses (mg/kg) based on individual patient response.
• Calculation of mean and standard deviation for optimal succinylcholine doses.

Main Results:

• Out of 500 patients, 180 (36%) required dose adjustments.
• 119 patients needed increased doses, while 61 patients required decreased doses from the 0.9 mg/kg standard.
• 5.8% of patients (29) required doses outside the 2 SD range, with effective doses from 0.29 mg/kg to 2.10 mg/kg.

Conclusions:

• A significant proportion of patients require succinylcholine doses outside the typical 0.9 mg/kg range for effective neuromuscular blockade during ECT.
• The effective dose range for succinylcholine in ECT can extend significantly higher (up to 2.10 mg/kg) or lower (down to 0.29 mg/kg) than the standard mean.
• Individualized dosing strategies are critical for optimizing succinylcholine use in ECT.